Implantica Expands Reach with Careggi University Hospital Adoption
VADUZ, Liechtenstein – Implantica AG (publ.), a pioneering medtech firm specializing in innovative body technology, is thrilled to announce that Careggi University Hospital has adopted its groundbreaking device, RefluxStop®, designed to treat acid reflux (GERD). This advancement comes amidst a global landscape where GERD affects over one billion individuals.
Dr. Paolo Prosperi, Chief of Emergency Surgery at Careggi, successfully led the first RefluxStop® procedure with assistance from Dr. Alessio Giordano. Careggi University Hospital, part of the esteemed University of Florence, is recognized as a premier medical institution in Italy, emphasizing innovation in surgical methods. This strategic move highlights Implantica's commitment to integrating its advanced technologies within major European healthcare systems, facilitating wider access for patients in need.
Dr. Prosperi expressed his enthusiasm, stating, "The introduction of RefluxStop represents a major leap forward in GERD management. Unlike traditional anti-reflux surgeries that encircle the esophagus, RefluxStop® addresses the issue without the common drawbacks, therefore positioning itself as a superior option for patients. I am eager to utilize this revolutionary approach to aid those suffering from GERD in Tuscany and surrounding areas, enhancing their quality of life in profound ways."
Dr. Peter Forsell, the innovator behind RefluxStop® and CEO of Implantica, extended his congratulations to Dr. Prosperi. Forsell noted, "We recognize GERD as a substantial unmet need affecting nearly 20% of the Italian population. With over 1,400 patients treated with RefluxStop® across Europe, the outcomes have been consistently positive, including for patients who once had limited treatment choices. The adoption of RefluxStop® by a leading institution like Careggi underscores the growing trust in this therapy, which we aim to implement at leading centers throughout Europe. This is a promising step for the healthcare community as we strive to improve patient experiences."
As the landscape of GERD treatment evolves, RefluxStop® sets itself apart with a unique mechanism that reinforces the body’s natural anti-reflux barrier, restoring balance without traditional surgical risks. This innovative approach allows patients to potentially return to a more normal lifestyle without the adverse side effects related to conventional methods.
Company and Contact Information
Implantica is publicly traded on the Nasdaq First North Premier Growth Market in Stockholm. The company's contact for corporate affairs is Nicole Pehrsson, Chief Corporate Affairs Officer, who can be reached at +41 (0)79 335 09 49.
Implantica’s focus extends beyond GERD solutions; the company is dedicated to integrating eHealth technology with its products. Their pipeline is robust, with innovative solutions aimed at monitoring health parameters, offering remote treatment options, and ensuring ease of communication with caregivers, all designed to enhance life quality.
About RefluxStop®
RefluxStop® represents a shift in how acid reflux can be effectively managed. Unlike traditional surgeries that impose physical constraints, RefluxStop® offers a non-invasive solution that maintains the lower esophageal sphincter's function without applying pressure. The device aims to restore and support the anatomical structure responsible for preventing acid reflux, offering hope to countless individuals seeking relief.
Frequently Asked Questions
What is RefluxStop®?
RefluxStop® is an innovative medical device designed to treat GERD without the side effects associated with traditional surgeries by restoring the body's natural protective mechanisms.
Where has RefluxStop® been adopted?
RefluxStop® has been recently adopted by Careggi University Hospital, a leading medical institution in Italy, allowing for expanded patient access to this technology.
Who performed the first RefluxStop® procedure?
The first RefluxStop® procedure at Careggi University Hospital was successfully performed by Dr. Paolo Prosperi, enhancing treatment options for GERD patients.
How does RefluxStop® work?
RefluxStop® functions by restoring the lower esophageal sphincter's natural position, preventing reflux without encircling the esophagus, making it a safer alternative.
What impact does Implantica aim to achieve with RefluxStop®?
Implantica aims to improve the quality of life for GERD patients by providing an effective solution that minimizes side effects, thus enhancing overall treatment outcomes.
